Please login to the form below

Not currently logged in
Email:
Password:

McKesson

This page shows the latest McKesson news and features for those working in and with pharma, biotech and healthcare.

J&J, distributors reach $26bn settlement to address the opioid crisis in the US

J&J, distributors reach $26bn settlement to address the opioid crisis in the US

Breaking down the settlement, the three named distributors – Cardinal, McKesson and AmerisourceBergen – will pay up to $21bn over 18 years.

Latest news

  • Mallinckrodt reaches tentative $1.6bn opioid settlement Mallinckrodt reaches tentative $1.6bn opioid settlement

    One such solution was a wide-ranging, $18bn proposal offered by the ‘big three’ US pharma wholesalers – McKesson, AmerisourceBergen and Cardinal Health – although this was wholly rejected by at least 21

  • US states reject drug distributors’ opioid settlement US states reject drug distributors’ opioid settlement

    McKesson, AmerisourceBergen and Cardinal Health had offered the amount over an 18-year period, but the WSJ understands the states want a larger settlement of $22bn to $32bn, or a shorter ... McKesson said that it was prepared to defend itself in court,

  • US start-up EQRx promises approach that will slash drug prices US start-up EQRx promises approach that will slash drug prices

    Other key figures in EQRx include former Foundation Medicine and McKesson executive Melanie Nallicheri, who serves as president and chief operating officer.

  • The year in review The year in review

    In 2019, we saw an avalanche of legal manoeuvrings and proposed settlements with companies like Purdue, Johnson and Johnson, McKesson, AmeriSource Bergen, Cardinal Health and Teva now offering to pay jurisdictions

  • UPDATED: Ohio opioid trial averted by last-minute settlement UPDATED: Ohio opioid trial averted by last-minute settlement

    Polster spent a busy day last Friday handling meetings between state attorneys general, lawyers for local authorities and top executives of the US’ largest three wholesalers – AmerisourceBergen, Cardinal Health and McKesson – ... The deal, which

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Celesio / McKesson. Acquisition. Wholesaler and pharmacy chains   . 8, 300. Mitokyne / Astellas.

  • Pharma deals during October 2013 Pharma deals during October 2013

    As part of the deal, McKesson will gain over $30bn in annual revenues and the resulting pharmacies/wholesale group will have revenues in excess of $150bn. ... This offer values Celesio (including debt) at approximately 11 times expected EBITDA for this

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • NHS names ‘procurement champion’ NHS names ‘procurement champion’

    UK head of US-owned healthcare firm McKesson.

  • 3WON adds to board 3WON adds to board

    Hickey, a director of WellCare Health Plans, and a trustee of Nantucket Cottage Hospital, is a former president of D2Hawkeye (now Verisk Health) and IntelliClaim, acquired by McKesson Corporation.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • McKesson International (UK)

    McKesson is the trusted healthcare technology solutions and services provider dedicated to helping its customers deliver high-quality healthcare by reducing costs, streamlining processes, and improving the quality and safety of ... McKesson International

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....